文献速递艾滋病与性传播感染

头孢克肟对比苄星青霉素G治疗早期梅毒的随机对照开放标签试验

Cefixime versus benzathine penicillin G for the treatment of early syphilis-a randomized, controlled open label trial.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该随机对照开放标签试验将61例确诊早期梅毒患者分配至头孢克肟400mg口服每日两次连用14天组或苄星青霉素G 2.4 MIU单次肌注组,比较治疗后3个月和12个月VDRL滴度下降≥4倍的比例。意向性分析显示3个月时头孢克肟组22/30(73.3%)、青霉素组27/31(87.1%)达到主要终点,12个月时分别为28/30(93.3%)和30/31(96.8%),两组耐受良好且无严重不良事件。

要点

  • 头孢克肟400mg口服每日两次连用14天对早期梅毒显示有效且安全。
  • 3个月VDRL滴度下降≥4倍比例头孢克肟组73.3%、青霉素组87.1%。
  • 12个月时两组血清学应答比例分别为93.3%和96.8%。

核心结论

  • 口服头孢克肟可能是治疗早期梅毒的有效且安全方案,但需更大规模研究进一步验证疗效。

研究设计与样本

  • 随机对照开放标签试验,纳入61例确诊早期梅毒患者,随机分配至头孢克肟400mg口服每日两次连用14天组或苄星青霉素G 2.4 MIU单次肌注组。

主要发现

  • 意向性分析中,治疗后3个月VDRL滴度下降≥4倍者头孢克肟组为22/30(73.3%),苄星青霉素G组为27/31(87.1%)。
  • 治疗后12个月VDRL滴度下降≥4倍者头孢克肟组为28/30(93.3%),苄星青霉素G组为30/31(96.8%)。
  • 两种治疗均耐受良好,未报告严重不良事件或严重程度的不良事件。

关键数值与推荐

  • 主要结局为治疗后3个月VDRL滴度较基线下降≥4倍(≥2个稀释度)。
  • 次要结局为治疗后12个月VDRL滴度较基线下降≥4倍(≥2个稀释度)。

临床怎么用

  • 对于早期梅毒,口服头孢克肟400mg每日两次连用14天可作为潜在替代方案,但当前证据有限,应优先遵循指南推荐。

局限性

  • 样本量较小(61例随机),需更大规模治疗研究提供额外疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cefixime is a promising oral treatment alternative for early syphilis but only very limited efficacy data exist. We evaluated the efficacy and safety of cefixime for the treatment of early syphilis. METHODS: A randomized controlled, open label trial in patients with confirmed early syphilis who were randomized to treatment with cefixime 400 mg orally twice a day for 14 consecutive days or to a single dose of benzathine penicillin G (BPG) 2.4 MIU intramuscular. The outcome was a 4-fold or more (≥2 dilution steps) decrease in Venereal Disease Research Laboratory test (VDRL) titre from baseline to 3 months (primary outcome) or 12 months (secondary outcome) after the treatment. RESULTS: Of 61 randomized patients, 58 (95.1%) completed the study (28 patients in the cefixime arm and 30 in the BPG arm). In the intention to treat analysis, the primary endpoint was achieved after 3 months in 22 of 30 (73.3%) of patients in the cefixime arm and 27 of 31 (87.1%) in the BPG arm, and after 12 months in 28 of 30 (93.3%) of patients in the cefixime arm and 30 of 31 (96.8%) of patients in the BPG arm. Both treatments were well tolerated and no serious adverse events or adverse events with severe intensity were reported. CONCLUSIONS: The results from our study are consistent with current limited knowledge and suggest that oral cefixime can be an effective and safe therapy for the treatment of early syphilis. However, additional efficacy data from larger treatment studies are imperative.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Klementová T, Zákoucká H, Bížová B, et al. Cefixime versus benzathine penicillin G for the treatment of early syphilis-a randomized, controlled open label trial. J Antimicrob Chemother. 2025. PMID: 40795115. doi:10.1093/jac/dkaf268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。